Plexin domain-containing 1 may be a biomarker of poor prognosis in hepatocellular carcinoma patients, may mediate immune evasion

Table 1 The clinical information of 123 patients with hepatocellular carcinoma

Clinicopathological features	Number	Low expression, n (%)	High expression, n (%)	P value
Age
< 60	68	51 (75.0)	17 (25.0)	0.467
≥ 60	55	40 (72.7)	15 (27.3)
Gender
Male	102	76 (74.5)	26 (25.5)	0.480
Female	21	15 (71.4)	6 (28.6)
Tumor size
≤ 5 cm	65	49 (75.4)	16 (24.6)	0.432
> 5 cm	58	42 (72.4)	16 (27.6)
Cirrhosis
Negative	63	53 (84.1)	10 (15.9)	0.007a
Positive	60	38 (63.3)	22 (36.7)
ALBI score
≤ -2.60	55	40 (72.7)	15 (27.3)	0.001a
> -2.60	68	51 (75.0)	17 (25.0)
APRI score
> 2	38	26 (68.4)	12 (31.6)	0.010a
≤ 2	85	65 (76.5)	20 (23.5)
AFP (ng/mL)
≤ 20	42	36 (85.7)	6 (14.3)	0.025a
> 20	81	55 (67.9)	26 (32.1)
HBV
Negative	12	8 (66.7)	4 (33.3)	0.381
Positive	111	83 (74.8)	28 (25.2)
Intrahepatic metastasis
Negative	111	82 (73.9)	29 (26.1)	0.619
Positive	12	9 (75.0)	3 (25.0)

^aP < 0.05.

ALBI: Albumin-bilirubin; APRI: Aspartate aminotransferase to platelet ratio; AFP: Alpha-fetoprotein; HBV: Hepatitis B virus.